Tags

Type your tag names separated by a space and hit enter

Trends in antimicrobial susceptibilities among bacterial pathogens isolated from patients hospitalized in European medical centers: 6-year report of the MYSTIC Surveillance Study (1997-2002).
Diagn Microbiol Infect Dis. 2005 Apr; 51(4):281-9.DM

Abstract

The Meropenem Yearly Susceptibility Test Information Collection (MYSTIC) Program provides antimicrobial susceptibility data. The activity of meropenem and 7 broad-spectrum antimicrobials have been examined against 12645 bacterial isolates from 14 European centers between 1997 and 2002. Cumulative susceptibility rates against all species of Enterobacteriaceae combined were ranked as follows: meropenem (99.9%) > imipenem (97.7%) > ciprofloxacin (86.0%) > piperacillin-tazobactam (85.6%) > ceftazidime (85.4%) > gentamicin (85.4%) > tobramycin (85.0%) > cefotaxime (83.8%). The carbapenems were also found to be the most active of the classes tested against nonfermentative Gram-negative bacilli. Against methicillin-susceptible Staphylococcus aureus and coagulase-negative staphylococci, all beta-lactams tested (except ceftazidime) had susceptibility rates of > or = 99.0% and > or = 94.3%, respectively. Over the 6-year period, there was no loss of activity or increase in resistance rate for either carbapenem against any of the species tested. These data confirm the continued potency and broad-spectrum activity of meropenem in units where it is actively being prescribed.

Authors+Show Affiliations

Infection Therapy Area, AstraZeneca, Macclesfield, SK10 4TG Cheshire, UK. philip.turner@astrazeneca.com

Pub Type(s)

Journal Article
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

15808320

Citation

Turner, Philip J.. "Trends in Antimicrobial Susceptibilities Among Bacterial Pathogens Isolated From Patients Hospitalized in European Medical Centers: 6-year Report of the MYSTIC Surveillance Study (1997-2002)." Diagnostic Microbiology and Infectious Disease, vol. 51, no. 4, 2005, pp. 281-9.
Turner PJ. Trends in antimicrobial susceptibilities among bacterial pathogens isolated from patients hospitalized in European medical centers: 6-year report of the MYSTIC Surveillance Study (1997-2002). Diagn Microbiol Infect Dis. 2005;51(4):281-9.
Turner, P. J. (2005). Trends in antimicrobial susceptibilities among bacterial pathogens isolated from patients hospitalized in European medical centers: 6-year report of the MYSTIC Surveillance Study (1997-2002). Diagnostic Microbiology and Infectious Disease, 51(4), 281-9.
Turner PJ. Trends in Antimicrobial Susceptibilities Among Bacterial Pathogens Isolated From Patients Hospitalized in European Medical Centers: 6-year Report of the MYSTIC Surveillance Study (1997-2002). Diagn Microbiol Infect Dis. 2005;51(4):281-9. PubMed PMID: 15808320.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Trends in antimicrobial susceptibilities among bacterial pathogens isolated from patients hospitalized in European medical centers: 6-year report of the MYSTIC Surveillance Study (1997-2002). A1 - Turner,Philip J, PY - 2004/07/20/received PY - 2004/11/09/accepted PY - 2005/4/6/pubmed PY - 2005/7/8/medline PY - 2005/4/6/entrez SP - 281 EP - 9 JF - Diagnostic microbiology and infectious disease JO - Diagn. Microbiol. Infect. Dis. VL - 51 IS - 4 N2 - The Meropenem Yearly Susceptibility Test Information Collection (MYSTIC) Program provides antimicrobial susceptibility data. The activity of meropenem and 7 broad-spectrum antimicrobials have been examined against 12645 bacterial isolates from 14 European centers between 1997 and 2002. Cumulative susceptibility rates against all species of Enterobacteriaceae combined were ranked as follows: meropenem (99.9%) > imipenem (97.7%) > ciprofloxacin (86.0%) > piperacillin-tazobactam (85.6%) > ceftazidime (85.4%) > gentamicin (85.4%) > tobramycin (85.0%) > cefotaxime (83.8%). The carbapenems were also found to be the most active of the classes tested against nonfermentative Gram-negative bacilli. Against methicillin-susceptible Staphylococcus aureus and coagulase-negative staphylococci, all beta-lactams tested (except ceftazidime) had susceptibility rates of > or = 99.0% and > or = 94.3%, respectively. Over the 6-year period, there was no loss of activity or increase in resistance rate for either carbapenem against any of the species tested. These data confirm the continued potency and broad-spectrum activity of meropenem in units where it is actively being prescribed. SN - 0732-8893 UR - https://www.unboundmedicine.com/medline/citation/15808320/Trends_in_antimicrobial_susceptibilities_among_bacterial_pathogens_isolated_from_patients_hospitalized_in_European_medical_centers:_6_year_report_of_the_MYSTIC_Surveillance_Study__1997_2002__ L2 - https://linkinghub.elsevier.com/retrieve/pii/S0732-8893(04)00239-1 DB - PRIME DP - Unbound Medicine ER -